To summarize the roles of insulin-like growth factor binding proteins (IGFBPs) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and their potential as biomarkers and therapeutic targets, as indicated by recent studies.
Key Findings:
IGFBP1 and IGFBP2 promote lipid oxidation and increase insulin sensitivity, as supported by recent studies.
IGFBP3 and IGFBP5 restrain lipogenesis early but promote hepatocellular injury and stellate cell activation during fibrosis, according to recent findings.
IGFBP7 impairs insulin signaling, drives ferroptosis, and fosters fibrosis, as indicated by current research.
IGFBP4 and IGFBP6 are less well characterized in the context of MASLD, requiring further investigation.
Interpretation:
The review emphasizes the complex roles of IGFBPs in MASLD, suggesting their potential as biomarkers and therapeutic targets, as indicated by the findings.
Limitations:
The roles of IGFBP4 and IGFBP6 in MASLD are not well characterized, necessitating further research.
Current understanding of IGFBPs in MASLD is based on emerging evidence and may require further validation from additional studies.
Conclusion:
The review provides a comprehensive summary of IGFBPs' contributions to MASLD, indicating their potential roles in disease progression and as therapeutic targets, as supported by recent findings.
